Who
Scott Biller
Director
Company insider
Files Form 4 as: Director, Foghorn Therapeutics; Chief Scientific Officer, Agios Pharmaceuticals.
In numbers
- Trades disclosed
- 271
- Buys
- 0
- Sells
- 58
- Bought
- $0
- Sold
- $24.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 21 Jan 2014
- Last trade
- 24 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 17 Jun 2025filed 17 Jun 2025 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $120K25,000 at $4.79 | filing |
| 26 Jun 2024filed 28 Jun 2024 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $88K16,000 at $5.52 | filing |
| 21 Jun 2023filed 22 Jun 2023 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 21 Jun 2022filed 22 Jun 2022 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 13 Jul 2021filed 14 Jul 2021 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,530 at $0.00 | filing |
| 11 Jun 2019filed 13 Jun 2019 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,218 at $0.00 | filing |
| 11 Jun 2019filed 13 Jun 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $17K7,218 at $2.34 | filing |
| 5 Apr 2019filed 9 Apr 2019 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 5 Apr 2019filed 9 Apr 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $119K3,000 at $39.76 | filing |
| 5 Apr 2019filed 9 Apr 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $162K2,401 at $67.61 | filing |
| 5 Apr 2019filed 9 Apr 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $41K599 at $68.12 | filing |
| 5 Mar 2019filed 7 Mar 2019 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —428 at $0.00 | filing |
| 5 Mar 2019filed 7 Mar 2019 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,572 at $0.00 | filing |
| 5 Mar 2019filed 7 Mar 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $14K428 at $31.64 | filing |
| 5 Mar 2019filed 7 Mar 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $102K2,572 at $39.76 | filing |
| 5 Mar 2019filed 7 Mar 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $13K200 at $66.45 | filing |
| 5 Mar 2019filed 7 Mar 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $176K2,600 at $67.73 | filing |
| 5 Mar 2019filed 7 Mar 2019 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $14K200 at $68.22 | filing |
News
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Scott Biller; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.